Characteristics of different types of Helicobacter pylori: New evidence from non-amplified white light endoscopy

Abstract

BackgroundDifferent types of Helicobacter pylori (H. pylori) were analyzed to determine their infection characteristics using serology, pathology, and non-magnification white light endoscopy combined with the Kimura–Takemoto classification, and the regular arrangement of collecting venules (RAC) as well.Materials and methodsA retrospective analysis of 685 inpatients who have completed the 14C-urea breath test, the H. pylori antibody typing classification, the serum gastric function tests (PGI/PGII/G-17), the endoscope detection, and the pathological examinations.ResultsThe levels of PGI, PGII, and G-17 were in descending order from the type I H. pylori infection group to the type II H. pylori infection group than the control group (F = 14.31; 26.23; 9.12, P < 0.01). Using the Kimura–Takemoto classification, there were significant differences among the three groups of different degrees of atrophy (χ2=29.81; 482.78; 292.5, P< 0.01). Based on the characteristics of RAC, the H. pylori infection rates were in descending order from the type I H. pylori infection group to the type II H. pylori infection group than the control group (χ2= 200.39; 174.72; 143.51, P < 0.01). The type I H. pylori infection group had higher grades than those of the type II H. pylori infection group in the OLGA and OLGIM staging systems, while the differences are statistically significant only in the OLGA staging system (χ2=10.63, P < 0.05).ConclusionWith the aid of non-amplified white light endoscopy, we found new evidence of type I H. pylori infection accelerating the progression of gastric mucosal atrophy through the degree of atrophy and the range of infection, whereas type II H. pylori infection has a low ability of migration and atrophy progression. Individual virulence factor-based eradication therapy may be a better choice in future.

Bioactive peptides as alternative treatment for Helicobacter pylori infection

“…As previously noted, the majority of patients infected with H. pylori exhibit histologic gastritis, and the phenotype of this gastritis will influence the progression of symptoms [48][49][50]. Most of the patients have a mild gastritis phenotype that in general is asymptomatic and do not affect the acid secretion, 10 to 15% presents the duodenal ulcer phenotype that affects the secretory function with a higher production of gastrin and acid secretion, with disturbances in the inhibitory control of acid secretion leading to dyspeptic symptoms and/or duodenal ulcer, and less than 1% present the gastric cancer phenotype that culminates in a strong reduction or absence of acid secretion, leading to severe atrophic gastritis, intestinal metaplasia and gastric cancer [21,34,[51][52][53].…”

Novel MAXPOWER biological antibacterial liquid for eradicating oral Helicobacter pylori

“…Subsequent extensive clinical and basic research on Helicobacter pylori further confirmed its close association with gastric cancer. In 2022, chronic Helicobacter pylori infection was officially defined as a definite carcinogen [ 5 , 6 ]. Thus, the eradication of H. pylori is of great clinical significance in achieving the goal of reducing or eliminating deaths associated with gastric cancer [ 7 ].…”